October 28, 2026

Etentamig significantly improves response, PFS for patients with heavily pretreated myeloma in the CERVINO trial

Ententamig is a second-generation bispecific T-cell engager targeting CD3 and B-cell maturation antigen with a low-affinity CD3 binding domain, potentially reducing rates of cytokine release syndrome (CRS) and infection, wrote the study’s authors, led by Peter Voorhees, MD, of Atrium health Levine Cancer Institute in Charlotte, North Carolina.

Read More ➔
EMA (European Medicines Agency Of European Union) Modern Tower Building Facade Logo Sign, Corporate Skyscraper Exterior, Canary Wharf, Global Financial District, London, England, UK, June 2025

CHMP backs talquetamab combinations for relapsed or refractory multiple myeloma

The European Medicines Agency Committee for Medicinal Products for Human Use has recommended an indication extension for talquetamab (TALVEY) plus daratumumab with or without pomalidomide; the recommendation covers adults with relapsed or refractory multiple myeloma who have received at least one prior therapy, according to a press release from the drug’s manufacturer, Johnson and Johnson. 

Read More ➔
Mother holding child hand with saline IV solution in hospital

Blinatumomab effectively replaces conventional chemotherapy cycles for pediatric patients with B-ALL

The study’s authors, led by Marin Schrappe, MD, of Christian Albrechts University Kiel and University Hospital Schleswig-Holstein in Germany, enrolled pediatric patients with high-risk B-ALL to receive two cycles of either blinatumomab or control chemotherapy after consolidation therapy. The primary end point was EFS based on a time-to-event analysis. 

Read More ➔

Top Categories

POPULAR NEWS

Featured Jobs

No jobs available.
Society of Hematologic Oncology

SOHO Insider Podcast

SOHO Insider Print

Trending Now

Meetings

Young Investigator Program

Ambassador Program

MEMBERS

About Us/Editorial Board

SOHO Insider is the official media platform of the Society of Hematologic Oncology. The SOHO Insider Editorial Board is comprised of leading hematologists. Learn more about our editorial board and SOHO Insider platforms.

A global hematologic oncology medical community

Download the SOHO365 mobile app & join our Ask-the-Expert forums

Submit your difficult clinical questions to the Ask-the-Expert forum in the SOHO mobile app. Submit your questions in our exclusive members-only forums community on the SOHO mobile app. Your inquiry will be sent directly to leading experts, including Dr. Hagop Kantarjian, Dr. Kami Maddocks, Dr. Sagar Lonial, and Dr. Mascarenhas for their insights.

Follow the instructions below to ask a question now!

Members Strong

Join Us Today and Become a Part of the SOHO Community

Benefits of membership include:

Career

SOHO Career Center

The Career Center provides SOHO members with the ability to find jobs in the field of Hematologic Oncology along with a variety of career advice. Select the 'Career Center' button to explore new job opportunities and career information.

The Career Center Allows SOHO Members to:

To access the SOHO Career Center click the following link.